OR WAIT null SECS
© 2023 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
The new method was developed to isolate tissue-specific EVs from the blood in addition to using a workflow to analyze their diverse multi-omics content.
Murlsa Bio’s tissue-specific Extracellular Vesicle (EV) isolation technology, NEXPLOR, will be presented at the International Society for Extracellular Vesicles (ISEV) annual meeting, which is intended to be a new route for biomarker discovery in liquid biopsy and precision medicine.
The new method was developed to isolate tissue-specific EVs from the blood in addition to using a workflow to analyze their diverse multi-omics content. The ISEV annual meeting will continue to showcase NEXPLOR and how it has been used to discover novel liver cancer biomarkers for the surveillance of individuals at high risk.
“NEXPLOR can isolate specific sub-populations of EVs, such as liver-specific EVs, from complex fluids like blood. This is an important step forward to develop EV-based liquid biopsy and precision medicine applications,” said Tomás Dias, PhD, CTO at Mursla Bio, in a press release.
NEXPLOR is engineered to improve the translation of EV-based diagnostics into clinics. Further, this complements its ultrasensitive validation technology, NEXOS, which was created to offer a high throughput and clinically compatible in vitro diagnostics test from the newly discovered panel of tissue-EV biomarkers, according to the press release.
“Imagine you could examine any bodily tissue, at any time, without resorting to invasive procedures. This would completely transform how we manage cancer and chronic disease. The liquid biopsy field has been built on that principle,” said Pierre Arsène, founder and CEO of Mursla Bio, in a press release. “Unfortunately, existing approaches based on circulating free DNA have been restrictive, providing only a limited snapshot of cellular activity. This is because they are not tissue-specific and overlook the complexity of biological processes. We believe our method marks a substantial progression and have initiated a clinical study to deliver our first liquid biopsy test, which we expect to complete by early 2024. We aim to launch in the US in 2025.”
Source: Mursla Bio